Pfizer raised its full-year 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion, while BioNTech cut its full-year 2026 revenue guidance to €1.6 billion to €1.9 billion from a prior range of €2.0 billion to €2.3 billion and announced that co-founder and CEO Prof. Ugur Sahin will step down to lead a new independent entity, with Guido Oelkers succeeding him as CEO by February 1, 2027. Pfizer reported Q2 2026 revenues of $15.0 billion, a 1% operational increase year-over-year, and adjusted diluted earnings per share of $0.77, while BioNTech's Q2 2026 revenues fell 59.5% year-over-year to €105.6 million and its IFRS net loss widened to €820.8 million. The European Commission authorized the companies' updated XFG-adapted COVID-19 vaccine on July 29. Pfizer also announced an expansion of productivity initiatives expected to yield $2.5 billion in additional savings between 2027 and 2029, while BioNTech maintains €16.6 billion in cash, cash equivalents, and security investments to fund its oncology pipeline.
BioNTech SEBioNTech cut 2026 revenue guidance and reported a widened net loss, though CEO transition is neutral.
Pfizer IncPfizer raised 2026 revenue guidance and reported Q2 earnings, with productivity savings.
